BIIB Latest Press Releases

-- October 22, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates Business Wire 8:00 AM

-- October 19, 2026 --

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week Globe Newswire 7:30 AM

-- October 5, 2026 --

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire 7:00 AM

-- October 2, 2026 --

Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus Globe Newswire 11:20 AM

-- September 23, 2026 --

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization Business Wire 4:01 PM

-- September 17, 2026 --

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN Globe Newswire 4:15 PM

-- September 16, 2026 --

LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Approved in Japan for the Treatment of Early Alzheimer's Disease Globe Newswire 2:00 AM

-- September 8, 2026 --

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach Globe Newswire 8:30 AM

-- September 3, 2026 --

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Globe Newswire 7:30 PM

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Business Wire 7:30 PM

LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China Globe Newswire 12:00 AM

-- September 2, 2026 --

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference Business Wire 8:00 AM

-- September 1, 2026 --

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Business Wire 7:30 AM

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Globe Newswire 7:30 AM

-- August 31, 2026 --

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (lecanemab) for Early Alzheimer's Disease Globe Newswire 7:30 PM

-- August 24, 2026 --

LEQEMBI IQLIK (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease Globe Newswire 8:04 AM

LEQEMBI IQLIK(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease PRNewswire 8:00 AM

-- August 6, 2026 --

Biogen Completes Acquisition of RayThera Inc. Globe Newswire 6:15 PM

-- August 5, 2026 --

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference Business Wire 8:00 AM

-- August 3, 2026 --

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- July 27, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates Business Wire 4:01 PM

-- July 16, 2026 --

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide PRNewswire 7:47 AM

-- July 15, 2026 --

Biogen Appoints Michael J. Parini as Chief Legal Officer Globe Newswire 8:15 AM

-- July 14, 2026 --

LEQEMBI Real-World LEADER Study Presented at AAIC 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment Globe Newswire 11:18 AM

LEQEMBI Real-World LEADER Study Presented at AAIC 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment PRNewswire 11:15 AM

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease Globe Newswire 9:15 AM

-- July 13, 2026 --

FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease Globe Newswire 5:38 PM

FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease PRNewswire 5:37 PM

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer Business Wire 7:30 AM

-- July 12, 2026 --

LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 Globe Newswire 11:18 AM

LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 PRNewswire 11:15 AM

-- June 30, 2026 --

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire 8:00 AM

-- June 29, 2026 --

Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. - BIIB Globe Newswire 8:00 AM

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen Globe Newswire 6:59 AM

-- June 22, 2026 --

International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma Globe Newswire 9:05 AM

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis Globe Newswire 8:30 AM

-- June 18, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PRNewswire 10:02 AM

-- June 17, 2026 --

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Globe Newswire 6:59 PM

-- June 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB Globe Newswire 6:45 PM

-- June 10, 2026 --

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 10:29 AM

-- June 4, 2026 --

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm Business Wire 8:58 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PRNewswire 10:08 AM

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy Globe Newswire 7:30 AM

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Globe Newswire 1:00 AM

-- June 3, 2026 --

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses Globe Newswire 7:30 AM

-- June 2, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB Globe Newswire 5:07 PM

-- June 1, 2026 --

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus Globe Newswire 1:30 AM

-- May 28, 2026 --

Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire 4:01 PM

-- May 26, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB Globe Newswire 4:50 PM

Market Data Delayed 15 Minutes